Author:
del Hoyo Pilar,García-Redondo Alberto,de Bustos Fernando,Molina José Antonio,Sayed Youssef,Alonso-Navarro Hortensia,Caballero Luis,Arenas Joaquín,Agúndez José AG,Jiménez-Jiménez Félix Javier
Abstract
Abstract
Background
In the substantia nigra of Parkinson's disease (PD) patients, increased lipid peroxidation, decreased activities of the mitochondrial complex I of the respiratory chain, catalase and glutathione-peroxidase, and decreased levels of reduced glutathione have been reported. These observations suggest that oxidative stress and mitochondrial dysfunction play a role in the neurodegeneration in PD. We assessed enzymatic activities of respiratory chain and other enzymes involved in oxidative processes in skin fibroblasts cultures of patients with PD.
Methods
We studied respiratory chain enzyme activities, activities of total, Cu/Zn- and Mn-superoxide-dismutase, gluthatione-peroxidase and catalase, and coenzyme Q10 levels in skin fibroblasts cultures from 20 Parkinson's disease (PD) patients and 19 age- and sex- matched healthy controls.
Results
When compared with controls, PD patients showed significantly lower specific activities for complex V (both corrected by citrate synthase activity and protein concentrations). Oxidized, reduced and total coenzyme Q10 levels (both corrected by citrate synthase and protein concentrations), and activities of total, Cu/Zn- and Mn-superoxide-dismutase, gluthatione-peroxidase and catalase, did not differ significantly between PD-patients and control groups. Values for enzyme activities in the PD group did not correlate with age at onset, duration, scores of the Unified Parkinson's Disease Rating scales and Hoehn-Yahr staging.
Conclusions
The main result of this study was the decreased activity of complex V in PD patients. This complex synthesizes ATP from ADP using an electrochemical gradient generated by complexes I-IV. These results suggest decreased energetic metabolism in fibroblasts of patients with PD.
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),General Medicine
Reference51 articles.
1. Nicklas WJ, Vyas I, Heikkila RE: Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sciences. 1985, 36: 2503-2508. 10.1016/0024-3205(85)90146-8.
2. Vyas I, Heikkila RE, Nicklas WJ: Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenyl-pyridinium. Journal of Neurochemistry. 1986, 46: 1501-1507. 10.1111/j.1471-4159.1986.tb01768.x.
3. Mizuno Y, Saitoh T, Sone N: Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity by 1-methyl-4-phenylpyridinium ion. Biochemical and Biophysica. Research Communications. 1987, 143: 294-299. 10.1016/0006-291X(87)90664-4.
4. Alonso-Navarro H, Jiménez-Jiménez FJ, Pilo de la Fuente B, Plaza-Nieto JF: Mecanismos patogénicos de la enfermedad de Parkinson. Tratado de los Trastornos del Movimiento. 2nd edition (ISBN 978-84-85424-76-4). Edited by: Jiménez-Jiménez FJ, Luquin MR, Molina JA, Linazasoro G. 2008, Barcelona: Viguera Editores S.L, 425-485.
5. Parker WD, Parks JK, Swerdlow RH: Complex I deficiency in Parkinson's disease frontal cortex. Brain Research. 2008, 1189: 215-218. 10.1016/j.brainres.2007.10.061.
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献